OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
028300$50300.0058

HLB Inc

Medical Equipment, Supplies & DistributionVerified

HLB Inc's capital structure is highly leveraged, with a debt-to-equity ratio of 0.68, indicating a moderate reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.36, which is significantly below the industry median. The firm's cash and equivalents of KRW 40.98 billion are insufficient to cover its long-term debt of KRW 284.95 billion, resulting in a negative net cash position. Profitability metrics are deeply negative, with a return on equity (ROE) of -52.69% and a return on assets (ROA) of -23.71%. These figures are far below the industry median for ROE and ROA, which typically range between 10-15% and 5-10%, respectively. The company reported a net loss of KRW 220.5 billion, with operating income also in negative territory at KRW -104.3 billion, indicating a severe operational underperformance. HLB Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. The company's revenue of KRW 84.17 billion is derived primarily from domestic operations, with no significant international exposure. This lack of diversification increases the company's vulnerability to domestic economic and regulatory shifts. The company's growth trajectory is negative, with no clear path to profitability in the near term. The outlook for the current fiscal year (FY) shows a continuation of declining performance, with no material revenue growth expected. The next FY is projected to remain under pressure, with no significant improvement in operating metrics. Historical revenue trends show a consistent decline, with no signs of stabilization. Risk factors for HLB Inc include a high liquidity risk due to its weak current ratio and negative net cash position. The company's dilution risk is currently low, as there is no indication of imminent share issuance or dilution events. However, the firm's financial distress could lead to future dilution if it requires additional capital to service its debt. Adjustments in the valuation model reflect the company's poor financial health and lack of earnings. Recent events include a significant net loss and negative operating cash flow, which have raised concerns among investors. The company has not disclosed any major strategic initiatives or cost-cutting measures in recent filings or transcripts. The absence of clear turnaround strategies or capital restructuring plans further exacerbates the company's risk profile.

30-day price · 028300-8100.00 (-14.8%)
Low$46500.00High$68500.00Close$46800.00As of22 May, 00:00 UTC
Profile
CompanyHLB Inc
Ticker028300.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. HLB Inc is a South Korean medical equipment and supplies company that generates revenue through the distribution and sale of healthcare products and services.

Classification. HLB Inc is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

HLB Inc's capital structure is highly leveraged, with a debt-to-equity ratio of 0.68, indicating a moderate reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.36, which is significantly below the industry median. The firm's cash and equivalents of KRW 40.98 billion are insufficient to cover its long-term debt of KRW 284.95 billion, resulting in a negative net cash position. Profitability metrics are deeply negative, with a return on equity (ROE) of -52.69% and a return on assets (ROA) of -23.71%. These figures are far below the industry median for ROE and ROA, which typically range between 10-15% and 5-10%, respectively. The company reported a net loss of KRW 220.5 billion, with operating income also in negative territory at KRW -104.3 billion, indicating a severe operational underperformance. HLB Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. The company's revenue of KRW 84.17 billion is derived primarily from domestic operations, with no significant international exposure. This lack of diversification increases the company's vulnerability to domestic economic and regulatory shifts. The company's growth trajectory is negative, with no clear path to profitability in the near term. The outlook for the current fiscal year (FY) shows a continuation of declining performance, with no material revenue growth expected. The next FY is projected to remain under pressure, with no significant improvement in operating metrics. Historical revenue trends show a consistent decline, with no signs of stabilization. Risk factors for HLB Inc include a high liquidity risk due to its weak current ratio and negative net cash position. The company's dilution risk is currently low, as there is no indication of imminent share issuance or dilution events. However, the firm's financial distress could lead to future dilution if it requires additional capital to service its debt. Adjustments in the valuation model reflect the company's poor financial health and lack of earnings. Recent events include a significant net loss and negative operating cash flow, which have raised concerns among investors. The company has not disclosed any major strategic initiatives or cost-cutting measures in recent filings or transcripts. The absence of clear turnaround strategies or capital restructuring plans further exacerbates the company's risk profile.
Key takeaways
  • HLB Inc is operating at a significant loss with a negative return on equity and assets.
  • The company's liquidity position is weak, with a current ratio of 0.36 and a negative net cash position.
  • Revenue is concentrated in a single business segment with no material geographic diversification.
  • Growth prospects are bleak, with no signs of improvement in the near term.
  • The company's capital structure is highly leveraged, increasing its financial risk.
  • No major strategic initiatives or cost-cutting measures have been disclosed in recent filings.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$84.17B
Gross profit$27.71B
Operating income-$104.31B
Net income-$220.50B
R&D
SG&A
D&A
SBC
Operating cash flow-$92.59B
CapEx-$17.53B
Free cash flow-$247.59B
Total assets$930.18B
Total liabilities$511.72B
Total equity$418.46B
Cash & equivalents$40.98B
Long-term debt$284.95B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$84.17B-$104.31B-$220.50B-$247.59B
FY-1$68.13B-$123.31B-$91.98B-$128.87B
FY-2$42.90B-$201.20B-$187.55B-$199.69B
FY-3$179.71B-$77.17B-$78.16B-$94.90B
FY-4$69.83B-$103.54B-$98.13B-$105.72B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$930.18B$418.46B$40.98B
FY-1$887.42B$576.57B$93.05B
FY-2$751.72B$523.89B$108.89B
FY-3$967.27B$637.94B$195.70B
FY-4$743.69B$435.96B$99.80B
PeriodOCFCapExFCFSBC
FY0-$92.59B-$17.53B-$247.59B
FY-1-$114.31B-$27.07B-$128.87B
FY-2-$111.63B-$7.06B-$199.69B
FY-3-$61.82B-$12.63B-$94.90B
FY-4-$54.77B-$6.14B-$105.72B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$18.69B-$23.19B-$38.00B-$39.78B
FQ-1$28.66B-$29.36B-$25.49B-$29.31B
FQ-2$22.11B-$23.03B-$73.09B-$83.48B
FQ-3$15.73B-$23.06B-$57.71B-$61.75B
FQ-4$17.66B-$28.76B-$64.21B-$73.05B
FQ-5$25.22B-$25.72B-$25.10B-$37.79B
FQ-6$16.95B-$19.56B$4.09B-$13.01B
FQ-7$14.79B-$37.47B-$103.26B-$107.05B
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$925.44B$414.93B$26.18B
FQ-1$930.18B$418.46B$40.98B
FQ-2$703.48B$377.32B$42.91B
FQ-3$745.33B$440.34B$53.00B
FQ-4$834.31B$513.95B$60.65B
FQ-5$887.42B$576.57B$93.05B
FQ-6$851.28B$523.56B$89.70B
FQ-7$778.91B$493.37B$69.49B
PeriodOCFCapExFCFSBC
FQ0-$17.75B-$615.8M-$39.78B
FQ-1-$92.59B-$17.53B-$29.31B
FQ-2-$58.15B-$16.11B-$83.48B
FQ-3-$47.06B-$7.76B-$61.75B
FQ-4-$24.47B-$5.46B-$73.05B
FQ-5-$114.31B-$27.07B-$37.79B
FQ-6-$91.22B-$17.50B-$13.01B
FQ-7-$68.82B-$2.21B-$107.05B
Valuation
Market price$50300.00
Market cap$6.68T
Enterprise value$6.93T
P/E
Reported non-GAAP P/E
EV/Revenue82.3
EV/Op income
EV/OCF
P/B16.0
P/Tangible book16.0
Tangible book$418.46B
Net cash-$243.96B
Current ratio0.4
Debt/Equity0.7
ROA-23.7%
ROE-52.7%
Cash conversion42.0%
CapEx/Revenue-20.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric028300Activity
Op margin-123.9%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin-262.0%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin32.9%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-20.8%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity68.0%69.3% medp25 63.4% · p75 74.5%below median
Observations
IR observations
market data ESG Score61.70 (0-100, higher is better)
Environment pillar66.79 (0-100)
Social pillar63.50 (0-100)
Governance pillar56.96 (0-100)
ESG controversies score100 (0-100, higher = fewer controversies)
ESG gradeB
Source: analysis-pipeline (hybrid)Generated: 2026-05-18 01:57 UTCJob: be0010bc